Unfounded. RGEN is more of a bio manufacturer than a bio tech/wonder drug company. Much more sustainable cash flow-- I would be a buyer here.
I understand the sector being down but this is way oversold IMO and we are going to see a very strong rebound in this stock. The fundamentals of the stock has not changed. I'm holding.
in the $25 is range?
Not fun that's for sure but stocks go up and down and have to endure these set backs or sell sell.......I choose to take the pain.......biotechs will recover and our story has not changed and should be solidified by another strong Q and we should be seeing an acquisition (hope hope!) to enhance growth.
Like Friday we saw very heavy selling most of the day and then some recovery in the last hr. or so.
Same thought......but we have been so fortunate that we have not reflected the poor biotech performance the past 3 months during this downtrend.......caught up to us today!
Reviewed the biotechs and they are really getting hammered with a sledge hammer!
Wow for anyone who wants to get in this would be a buying opportunity.......we have
been insulated from these SIGNIFICANT drops but today we are feeling da pain as
others have flet on days when MR MARKET IS PUKING!
It's been trading crazy for a month. Up $1 one day and down $1 the next. Wouldn't be surprised to see the stock up a few bucks on Monday. We shall see.
the other consideration with REPLIGEN.......we are so totally running with the biotechs (mostly good / very strong sector) and we are actually exhibiting strong relative strength as we have not taken as much of a hit over the past 3 months when the sector was puking.......love it love it!
inched over.......to mte this is an important benchmark and although volume is
very low like like like da last 2 weeks of relative strength....so looking good.
9/15/2015 (same article just a little further down.
Repligen Corporation (RGEN) is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs.
Apart from a Zacks Rank #2 (Buy), Repligen has a Growth Style Score of ‘B.’ The company has expected earnings growth of 40% for the current year.
two different companies.